• HOME
  • FAQs
  • NEWS
  • FULL PRESCRIBING INFORMATION
  • About VETMEDIN
    • Dual-acting inodilator
    • VETMEDIN
      in CHF
    |
  • About CHF|
    • Signs of CHF
    • AVVI
    • DCM
    • Diagnosing CHF
  • Act Now—Use VETMEDIN|
    • CHF treatment
    • Importance of acting now
    • 2009 ACVIM consensus statement
  • VETMEDIN Efficacy|
    • VetSCOPE
    • QUEST
  • Safety and Dosing|
    • Record of safe use
    • Dosage
  • VETMEDIN Programs

USEFUL LINKS

  • VETMEDIN Full Prescribing
    Information
  • Cardiac Education Group
  • YourDogsHeart.com
  • Boehringer Ingelheim Vetmedica, Inc.
  • American College of Veterinary
    Internal Medicine

VETMEDIN programs

Helping dogs with congestive heart failure (CHF) live longer, healthier lives is a top priority for Boehringer Ingelheim Vetmedica, Inc. That's why we support canine cardiology research and offer several programs to help veterinarians educate pet owners about the diagnosis and treatment of canine heart disease.

CE Webinar Series

The CE Webinar Series is an ongoing opportunity to learn about canine heart disease online—from the comfort of your own home or office. These online events are scheduled periodically throughout the year and are ideal for veterinarians who cannot attend a live dinner meeting.


Register for a CE Webinar

Important safety information

VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.

The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. The safe use of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. Use only in dogs with clinical evidence of heart failure.

Important safety information

VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricularvalvular insufficiency or dilated cardiomyopathy. The safe use of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. Use only in dogs with clinical evidence of heart failure. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. If side effects should occur, pet owners should contact their veterinarian. Please refer to the Full Prescribing Information here.

Home Site Map Terms of Use Privacy Contact About Boehringer Ingelheim Vetmedica,Inc.
VETMEDIN is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, licensed to Boehringer Ingelheim Vetmedica, Inc.
© 2015 Boehringer Ingelheim Vetmedica, Inc.